3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
127
Neoplasm Metastasis
18
Ovarian Neoplasms
12
Endometrial Neoplasms
9
Neoplasms
8
Triple Negative Breast Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
5
Prostatic Neoplasms
5
Hereditary Sensory and Autonomic Neuropathies
5
Colorectal Neoplasms
5
Advanced Breast Cancer
5
Squamous Cell Carcinoma of Head and Neck
4
Stomach Neoplasms
3
Recurrence
3
Neoplasms by Site
3
Head and Neck Neoplasms
3
Carcinoma, Lobular
3
Breast Diseases
3
Breast Cancer Metastatic
3
Uterine Neoplasms
2
Small Cell Lung Carcinoma
2
Multiple Endocrine Neoplasia Type 1
2
Melanoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Solid Tumors
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Interventions
Carboplatin
9
pembrolizumab
7
Pemetrexed
7
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Radiation
4
Nivolumab
4
Bevacizumab
4
Platinum
3
Paclitaxel
3
Mastectomy, Segmental
3
Cisplatin
3
Biopsy
3
fludarabine phosphate
2
durvalumab
2
capmatinib
2
aldesleukin
2
Taxes
2
Radiotherapy, Conformal
2
Radiosurgery
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
Anterior Temporal Lobectomy
2
1,2-diaminocyclohexaneplatinum II citrate
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Fulvestrant
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled